Navigation Links
Genetic Disorder Drug Helps Reverse Heart Muscle Enlargement
Date:5/30/2008

Mice given BH4 had lower production of toxic free radicals from hypertension, study finds

FRIDAY, May 30 (HealthDay News) -- Tests on mice suggest that the drug BH4 may hold promise as a treatment for people with enlarged hearts, says a Johns Hopkins University study.

Currently, BH4 is used to treat a genetic disorder called phenylketonuria (PKU), a metabolic disorder in which a toxic buildup of a molecule called phenylalanine can cause brain damage.

In this study, the Hopkins team found that BH4 stabilized the pumping function of failing, enlarged hearts in mice and significantly decreased the size of the heart muscle in just over a month.

"Our results show for the first time the pivotal role played by BH4 in stopping and reversing the weakening and damage done -- even in severe cases -- to the heart muscle as a result of hypertension and subsequent hypertrophy [enlargement]," senior investigator Dr. David Kass, a professor at the Johns Hopkins University School of Medicine and its Heart Institute, said in a prepared statement.

"This key evidence may help us develop new therapies that stop and reverse hypertrophy, preventing the disease from leading to end-stage heart failure and keeping affected individuals from needing heart-assist pumps or a treatment of last resort, the heart transplant," Kass said.

In this study, the researchers gave a daily dose of 5 milligrams of BH4 per 25 grams of body weight to 31 mice whose hearts were damaged by hypertension. This group of mice was compared to a group of mice with hypertension-damaged hearts who received a placebo.

After five weeks, the BH4 group showed "remarkable improvements" compared to the placebo group. Ejection-fraction measures of heart pumping function improved from 48 percent at the start of BH4 treatment to 59 percent by the end of the study. In the placebo group, average pumping function decreased from 48 percent to 35 percent.

Heart weight, as measured by muscle mass, decreased from an average of 290 milligrams at the start of BH4 treatment to an average of 209 milligrams by the end of the study. In the placebo group, average heart weight was 330 milligrams by the end of the study.

The BH4 group also showed improvements in other areas, including heart wall thickness, muscle cell size and fibrosis, and lowered production of dangerous free radicals.

The study was published in the May 20 issue of Circulation.

More information

The American Heart Association has more about heart failure.



-- Robert Preidt



SOURCE: Johns Hopkins University, news release, May 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. USC researchers identify genetic markers that predict efficacy of novel cancer drug
2. Common Genetic Variant Tied to Lung Cancer Risk
3. Determining genetic signature of lung tumors can help guide treatment
4. Will lung cancer recur? A genetic test may provide the answer
5. Genetic loci assigned for musical aptitude in Finnish families
6. Geneticists at the American Museum of Natural History trace the evolution of St. Louis encephalitis
7. Genetic links to impaired social behavior in autism
8. Genetic Engineering and Biotechnology News reports on early ADMET use
9. Combined physical and genetic map finds cancers ignition key
10. Research program focuses on genetic mutations and cancer risk
11. Pelosi: Genetic Information Nondiscrimination Act Will Protect Americans from Misuse of Genetic Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: